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Once versus thrice daily intramuscular gentamicin in children with
systemic infections
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Objective: To evaluate the clinical efficacy, pharmacokinetic profiles and nephrotoxicity o f once daily versus 
thrice daily doses o f intramuscular gentamicin in infants and children.
Design: A randomized trial.
Subjects: Patients between ages o f one month and eight years with clinically suspected or proven severe 
bacterial infection with no prior history o f aminoglycoside therapy.
Interventions: Patients were randomized to receive gentamicin once daily or thrice daily with the same total 
daily dose of 6 mg/kg body weight.
Main O utcom e Measures: Clinical efficacy, pharmacokinetic profiles and nephrotoxicity.
Results: A total of 107 children were enrolled in the study, and random ized to the intervention. The baseline 
characteristics were comparable. Only 74 patients who continued to receive gentamicin therapy beyond 48 
hours were evaluated. A favourable clinical response was found in 27/35 (77%)in the OD group and 32/39 
(82%)in the TD group (p=0.814). Only 52 patients (26 in each group) had pharmacokinetic profiles 
determined. A statistically significantly higher mean (SD) serum peak concentration was present in the OD 
[6.45 (1.95) pg/ml] group com pared to the TD group [2.75 (1.3) p-g/ml] (pcO.OOl). Trough concentrations in 
both groups were within the desired levels o f less than 2 pg/m l. Evidence o f  apparent nephrotoxicity was 
absent in both groups.
Conclusion: Compared to the recom mended thrice daily dosing, once daily administration o f intramuscular 
gentamicin in children achieves better therapeutic drug levels. The once daily intramuscular dose is more 
convenient for both patients and health workers, is less costly and should therefore be recom mended for use 
in children.
Introduction
Aainoglycosides are commonly used worldwide in the 
Mment of severe bacterial infections especially aerobic 
|mn-iiegative infections.1 Due to its low cost, gentamicin is 
Ittunonly used in developing countries. In the paediatric 
fenfical wardsat Harare Central Hospital (HCH), gentamicin 
ns the fifth most commonly used antimicrobial agent in
m ?
It is now generally accepted that peak concentrations of 
gentamicin greater than 4 pg/ml are necessary for optimum 
antibacterial efficacy and trough levels above 2 pg/ml are a
risk factor for toxicity.34 A review of aminoglycoside toxicity 
in infants in a small number of well designed studies has not 
shown a significant difference in rates of ototoxicity or 
nephrotoxicity between aminoglycoside treated paediatric 
patients and untreated control subjects.5 Clinical experience 
has shown that aminoglycosides have occasionally caused 
ototoxicity in children and although nephrotoxic effects have 
also been observed, these are usually transient.5
Intravenous administration of a single total daily dose of 
gentamicin results in transiently higher peak serum levels but 
reduced trough levels after a 24 hour period as compared to 
thrice daily dosage.6-7 Aminoglycosides cause concentration
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iliqwisons of the distributions of discrete or continuous 
gMes between the two study groups were done using the 
III’corrected Chi-squared test, the Fishers’ exact test or 
■Students’ ttest where appropriate. A result with a p value 
(ftwthan 0.05 was considered statistically significant.
Results
lAtotalof 107 children were enrolled in the study. There were 
$l>oysand 56 girls giving a male to female ratio of 1 to 1.1. 
Tie median age (Q,, QJ was five (three, 15) months. Of the 
M7 children, 49 (46%) received IM gentamicin OD and 58 
(J4%)received IM gentamicin thrice daily (Table I). The two 
pups were comparable with respect to the baseline 
Imcteristics of age, weight, nutritional status, sex and 
pao admission temperature.
table I : Baseline characteristics of 107 patients.
O D
T o ta l= 4 9
T D
T o ta l= 5 8 p *v a lu e
I k  |MF) 2 6 /2 3 2 5 /3 3 0 .4 0 5
Ig i in m onths' 4 .0 (3 ,9 ) 5 .5 (3 ,1 7 ) 0 .2 1 6
MghtKG 5 .2 (4 .3 ,6 .6 ) 5 .5 ( 4 7 ,8 .7 ) 0 .1 0 8
N M o n (Weigh! for age)
m 19 33
a t * 3 0 2 5 0 .0 9 4
Temperature" 3 8 .1 (0 .8 ) 3 7 .9 (0 .9 ) 0 .1 3 6
lhmpy received for < 4 6  hours 11 16
Therpy chenged after 4 8  hrs 3 3
Thanpy continued for > 4 8  hrs 35 39
'Man (1st and 3rd quartilesj.
’than (SO), 
ttaau daily.
It  M u  daily.
Twenty seven patients (25%) had therapy discontinued 
within 48 hrs, 11/49 in the OD (22%) and 16/58 in the TD 
pop (28%). Reasons for discontinuing therapy were 
bchaige within 48 hours (11), transfer to infectious disease 
hospitals (4), deaths (11), and change of therapy by the 
■ending physician (1). A further six patients were excluded 
because therapy was changed after completing 48 hours of 
gentamicin therapy. Therefore a total of 74 (70%) of the 
original study sample, 35 in the OD and 39 in the TD groups 
woe evaluable.
CSnical Diagnosis and Micro-organisms.
The74 patients who continued to receive gentamicin therapy 
beyond 48 hours were evaluated. Sixty four (86%) had 
(■eumonia with 32 patients in each group. Three patients had 
impetigo, two epticaemia and two suspected urinary tract 
affection in the TD group. In the OD group, two patients had 
•epticaemia and one septic arthritis.
Blood cultures yielded organisms in 23 (31%); 12 (34%) in 
fcODand 11 (25%)in the TD group (Table II). The majority 
(IS%) were gram-positive organisms. Eight out of 12 (67%) 
•ganisms in the OD and six out of 11 (55%) in the TD groups 
were sensitive to gentamicin at minimum inhibitory 
concentration (MIC) of less than 2 pg/ml.
Table II: Micro-organism isolated in 74 who received 
Gentamicin therapy for more than 48 hours.
OD T D
(T o ta ls35 (T o ta b 3 9 )  T o ta l
Staphylococcus aureus 5 2 7
Staphylococcus coagulase negative 4 2 6
Diphtheroids 1 1 2
Viridans group Steptococcus spp. 0 1 1
Streptococcus pneumoniae 0 1 1
Lactobacillus spp. 0 1 1
Salmonella/Arizona 
Escherichia coli
0
1
1
1
1
2
N LF coliforms 1 0 1
No growth 23 29 52
N LF—  Non-lactose fermenting.
Clinical Efficacy.
A favourable clinical response was found in 27 of the patients
in the OD (77%) and 32 (82%) in the TD group (p =0.814; 
Table III). All these patients also received parenteral beta- 
lactam antibiotics throughout the duration of their hospital
stay because of severe illness.
Table III: Clinical efficacy.
O D T D
T o ta l= 3 5 T o ta l= 3 9 p -v a lu e
W B C  on ad m ission 15.1 (8 .0 )' 15 .9 (10 .0 ) 0.891
W B C  on Discharge (1 0 3) 1 0 7 (4 .3 ) 1 0 .1 (4 .4 ) 0 .6 68
Days to normal temp. 3 .6 (2 .7 ) 3 .4 ( 2 .4 ) 0 .7 79
Discharged 2  T 32
D ied 8 7 0 .8 14
' Heart (SO).
~  Absolute numbers.
Bacteriological Response.
In patients with initial bacteraemia, blood cultures repeated 
after treatment yielded growth in only one patient each in the 
OD and TD groups, therefore achieving 80% bacteriological 
cure in both groups.
Pharmacokinetic Profiles.
Only 52 of the 74 (70%) had both serum peak and trough 
gentamicin levels determined, 26/35 (74%)in the ODand 26/ 
39 (67%)in the TD groups. The baseline characteristics of 
these two groups were similar.
The mean (SD) peak serum concentration of gentamicin 
was higher in the OD [6.45(1.95) pg/ml] than in the TD 
[2.75(1.32) pg/ml] group (p<0.001). Peak serum levels were 
greater than 4 pg/ml in 24 (92%) of the OD group but only 
three (12%) of the TD group (p<0.001). Two patients in the 
ODandnine in the TD group had undetectable peak gentamicin 
concentrations. All patients had serum peak gentamicin 
concentrations of less than 12 pg/ml except one patient in the 
OD group who had a level of 12.7 pg/ml.
The m edian (Q l, Q 3) trough serum gentam icin 
concentrations were comparable in the two groups: 0.40 
(0.18,0.72) |Jg/ml in the OD and 0.71 (0.55,0.96) pg/ml in the 
TD group (p=0.065). All trough levels were less than 2 pg/ml
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with the exception of one patient in the TD group with a level 
of 2.81 |ig/ml because the sample was accidently collected 
immediately after the gentamicin injection (Table IV).
Table TV: Gentamicin serum levels.
Serum Levels ng/ml
0 0
Tota l=26
TD
Total=26 p-value
Peak levels
>4pgA nl 24 3
<A ug/ml 0 14
Undetectable 2 9 <0.001
Trough levels
22  ug/ml 0 1
<2 yjg/lml 26 25
Undetectable 14 16 0 .8 85
The cumulative gentamicin doses in the OD and TD groups 
were 224 and 196 mgs respectively (p=0.505). The mean 
(SD) duration of therapy was just over five (2.8) days [5.2 
(2.9) days in the OD group and 5.3 (2.7) days in the TD 
group].
Nephrotoxicity.
Seventy two (90%) had baseline creatinine results available. 
Only 46 (64%) had repeat creatinine levels determined. Of 
the 46 patients evaluated for nephrotoxicity, 20/35 were in the 
OD group (57%) and 26/39 in the TD group (67%). Mean 
(SD) baseline serum creatinine was marginally significantly 
lower in the TD; 48.8 (17.5) pmol/1 than in the OD group; 58 
(14.2) (imol/1, p=0.051. The maximum mean (SD) serum 
creatinine during treatment was comparable in both groups; 
OD 56.4( 18.2) (imol/1 and TD 47.7(21.5) pmol/1. None of the 
patients had a creatinine rise of over 45 pmol/1 or reached a 
level of 100 p.mol/1.
Discussion
There is now substantial evidence that less frequent dosing of 
aminoglycosides such as oncedaily gentamicin might enhance 
or preserve the antibacterial efficacy while lowering the risk 
ofnephro- and ototoxicity.116This is because aminoglycosides 
have concentration-dependant antibacterial activity 
and prolongation of PAE with increase an in peak 
concentration.917
This the first study in children and infants over one month 
of age to compare clinical efficacy, pharmacokinetics and 
safety of OD versus TD intramuscular gentamicin. Pneumonia 
accounted for more than 80% of all infections. This is not 
surprising since up to a third of admissions in the paediatric 
wards at Harare Central Hospital are usually due to 
pneumonia.18 Young infants with severe pneumonia were 
treated with penicillin and gentamicin as recommended by 
the World Health Organisation.19
No difference in clinical efficacy was observed between the 
once and thrice daily intramuscular groups. This is comparable 
to other studies in which the intravenous route was used.20 In 
our study, gentamicin antibacterial efficacy could not be 
specifically evaluated because beta-lactam antibiotics were 
administered concurrently in all patients. However, in clinical
practice, these are commonly used in combination due to the 
theoretical synergistic effect.1
Higher peak serum concentrations have been associated 
with a higher bacterial kill.17 This study showed statistically 
significantly higher mean serum peak concentrations in the 
OD than the TD group. This finding was comparable to other 
studies where more than 50% of patients on multiple daily 
doses were found to have sub-therapeutic levels.21-22 Hence, 
once daily gentamicin dosing strategy might maximize its 
therapeutic potential.
Trough concentrations in the OD and TD groups were 
within the desired levels of less than 2 (ig/ml. In other studies 
lower trough levels were found in the once daily regime.111* 
The lower levels in the TD group in this study could be 
attributed to the fact that most patients in the TD group had 
sub-therapeutic or undetectable peak serum levels.
There was no difference observed in nephrotoxicity between 
the two regimes in this study as has also been shown in the few 
other studies.16-23 This could be partly explained by the 
exclusion of high risk patients from the study and also by the 
fact that a serum creatinine rise of more than 45 p.mol/1 might 
be a late marker of nephrotoxicity. Studies that have reported 
increased renal toxicity with the TD compared to OD regime 
used early markers of toxicity like phospholipiduria and 
urinary alanine aminopeptidase excretion.4
Risk factors found to be associated with renal toxicity in 
other studies were prolonged therapy (usually longer than 
seven days), initial higher creatinine levels, prolonged half- 
life and high gentamicin trough levels.24 Recent data suggest 
that persistently high trough levels rather than transiently 1 
high peak levels are responsible for aminoglycoside related 
toxicity.23-25
We did not evaluate ototoxicity because the majority (74%) 
of the patients were infants and brain evoked response 
audiometry was not available. A recent meta-analysis of 21 
randomized trials using intravenous gentamicin found no 
difference in the incidence of ototoxicity between single and 
multiple dosing regimes, but the power of the pooled trials to 
detect a meaningful difference was low. Audiometry testing 
and the reporting of vestibular toxicity need to be addressed 
in future studies.26
The power of the current study is 61 % based on the clinical 
efficacy criteria used for the sample size calculation at tin 
start of the study. The reduced power of the study can partly 
be explained by the high attrition rate within the first 72 how 
of the study. All children in this study received parenteral 
beta-lactam antibiotic in addition to gentamicin and therefore 
clinical efficacy is likely to assess theeffectof the combination 
of antibiotics. Also of note is the preponderance of gram- 
positive bacterial isolates in our study which makes the 
assessment of gentamicin efficacy difficult since the usual 
indication for using aminoglycosides is proven or suspected 
gram-negative infections.5
It is obvious that once daily gentamicin dosing is mon 
economical in terms of the nursing workload and the numta 
of disposable syringes and needles required. A once dail) 
injection also makes it convenient for patients to be managed 
in the outpatient setting, therefore potentially reducing lit 
duration of hospitalization in certain patients. From tfc*-
“ ICENTRAL AFRICAN JOURNAL OF MEDICINE Vol. 43 •  No. 3 •  1997
{M ints* perspective, one injection causes less pain and 
flmmfort than three injections a day.
Most important is that this study has shown that once daily 
iinnistration of IM gentamicin in children achieves the 
laired therapeutic drug levels in a significantly higher 
In|l0itk» of patients compared to the conventional thrice 
H y  dosing and with no apparent increased risk of 
Kphrotoxicity. The once daily intramuscular dose is more 
Jouvenient for both patients and health workers, is less costly 
id  should therefore be recommended for use in children.
Acknowledgements
The authors are grateful to the following: M edical 
Superintendent, Harare Hospital for allowing access to 
(Mien's; parents and children who participated in the study; 
■edical and nursing colleagues for their cooperation and help 
*d Professor PR Mason of the Department of Microbiology, 
Medical School.
We extend our thanks to the German Technical Agency 
(GTZ) Harare office for the financial support. WM Were was 
sponsored by MISEREOR.
References
1. Mattie H, Craig WA, Pechere JC. Determinations of 
efficacy and toxicity of aminoglycosides. JAntimicrob 
Chemother 1989;24:281-93.
2. Nhachi C, Kasilo O, Nathoo S. Drug prescribing in 
paediatric inpatients at Parirenyatwa and Harare Central 
Hospitals. Cent A frJ  Med 1992;38(2):57-62.
3. Nordstrom L, Ringberg H, Cronberg S, Tjemstrom O, 
Walder M. Does administration of an aminoglycoside 
in a single dose affect its efficacy and toxicity? J  
Antimicrob Chemother 1990;25:159-73.
I, Siber GR, Echeverria P, Paisley JW, Smith DH. 
Pharmacokinetics of gentamicin in children and adults 
J Infect Dis 1975;132:637-51. 
j. McCracken Jr GH. Aminoglycoside toxicity in infants 
and children. Am J  Med 1986;80 (suppl 6B): 172-7.
6. Hull JH, Sarubbi FA. Gentamicin serum concentrations 
pharmacokinetic predictors. Ann Intern Med 1976; 
85:183-89.
7. Knaus WK,Draper EA,Wagner DP, Zimmerman JE . 
APACHE II: a severity of disease classification. Crit 
Care Med 1985;13:818-9.
8. Shah PM, Ghahremani M, Gore FJ, Stille W. Bactericidal 
activity of antimicrobialss in dynamic kill-curve model. 
J Drug Develop 79&S;l(suppl 3):35-47.
9. Van der Auwera P, Klastersky J. Serum bactericidal 
activity and postantibiotic effect in serum of patients 
with urinary tract infections receiving high dose 
am ikacin. Antim icrob Agents Chemother 
1987;31:1061-8.
10. Skopnik H, Nies BA, WallrafR, Toster K, Heimann G. 
Gentamicin dosing strategy in neonates: influence on 
pharmacokinetics and in vitro bacterial activity. Europ 
J Paediatr 1991; 150:606.
11. Skopnik H, Heimann G. Once daily dosing in full term 
neonates. Paediatr Infect Dis J  1995;14:71-2.
12. Elhanan K, Siplovich L, Raz R. Gentamicin once daily 
versus thrice daily in children./Antimicrob Chemother 
1995;35:327-32.
13. Kaye D.Levison ME, Labovitz ED. The unpredictability 
of concentrations of gentamicin: pharmacokinetics of 
gentamicin in patients with normal and abnormal renal 
function. /  Infect Dis l974;130(2):150-4.
14. Essential Drugs list for Zimbabwe: Ministry of Health 
and Child Welfare, Republic of Zimbabwe,1994.
15. Cheesebrough M. Medical Laboratory Manual for 
Tropical Countries. Vol. II: Microbiology. Sevenoakes, 
UK: Butterworths, 1985: ch. 41-43.
16. Prins JM, Buller HR, Kuijper EJ, Tange RA,Speelman 
P. Once versus thrice daily gentamicin in patients with 
serious infections. Lancet 1993;341:335-39.
17. Moore RD, Lietman PS, Sm ith CR. Clinical response to 
aminoglycoside therapy: importance of the ratio of 
peak concentration to minimal inhibitory concentration. 
J Infect Dis 1987;155:93-9.
18. Nathoo KJ, Nkrumah FK, Ndlovu D, Nhembe M, Kowo 
H, Pirie DJ Acute respiratory tract in hospitalized 
children in Zimbabwe. Ann TropPaediatr 1993; 13:253- 
61.
19. World Health Organisation Programme for the control 
of Acute Respiratory Infections. Antibiotics in the 
treatment of acute respiratory tract infections in young 
children.(1990) Geneva WHO/ARI/90.10.
20. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman 
P. Once daily gentamicin versus once daily netilmicin 
in patients with serious infections: a randomized clinical 
trial. J  Antimicrob Chemother 1994; 33:823-35.
21. Parker SE, Davey PG. Practicalities of once daily 
aminoglycoside dosing. J  Antimicrob Chemother 
1993;31:4-8.
22. Parker SE, Davey PG. Once daily aminoglycoside 
dosing. Lancet 1993;341:346-7.
23. De Broe ME, Reuben AG, Verpooten GA. Choice of 
drug and dosage regimen: two important risk factors for 
aminoglycoside nephrotoxicity. Am J  Med 1986; 80 
(Suppl 6B): 115—8.
24. Smith CR, Lipsky JJ, Laskin OL, Heilman DB, Mellitis 
ED, Longstreth J, et al. Double blind comparison of 
nephrotoxicity and auditory toxicity of gentamicin and 
tobramycin. N Engl J Med 1980; 302:1106-9.
25. Bennet WW, Plamp CE, Gilbert DN, Parker R A, Porter 
GA. The influence of dosage regime on experimental 
gentamicin nephrotoxicity: Dissociation of peak levels 
from renal failure. J Infect Dis 1979; 140: 576-80.
26. Barza M, Ioannidis JPA, Capelleri JC, Lau J.Single or 
multiple daily doses of aminoglycosides: a meta­
analysis. BrMedJ  1996;312:338-43.
CENTRAL AFRICAN JOURNAL OF MEDICINE Vol. 43 •  No. 3 •  1997 67
This work is licensed under a 
Creative Commons
Attribution -  Noncommercial - NoDerivs 3.0 License.
To view a copy of the license please see: 
http://creativecommons.Org/licenses/bv-nc-nd/3.0/
This is a download from the BLDS Digital Library on OpenDocs
http://opendocs.ids.ac.uk/opendocs/
Institute of 
Development Studies
